# Our Research Galaxy Diagnostics was founded by academic researchers and continues to lead with science that’s transparent, published, and reproducible. We believe diagnostics must be grounded in data that providers can trust and that trust starts with evidence that’s available, validated, and clinically useful. ### Key Areas of Scientific Contribution - Digital PCR application in infectious disease diagnostics - Culture-based detection and clinical relevance of _Bartonella_ - Diagnostic strategies for vector-borne pathogens in chronic cases ### How Our Research Informs the Diagnostics We Deliver - All methods rigorously validated to ensure reproducibility, trust, and clinical utility - Peer-reviewed science informs every step of test development - Transparent methodology is available to providers on request [Learn About Our Testing Methods](/content/for-providers/index.html) ## Scientific Leadership Behind the Research Galaxy’s research leadership includes: [Dr. Edward Breitschwerdt \ Chief Scientific Officer and Bartonella research pioneer \ Read Bio](/content/about-us/meet-the-team/edward-breitschwerdt-dvm-dacvim-saim/index.html) [Dr. Jennifer Miller \ Vice President of Clinical and Scientific Operations; CLIA Laboratory Technical Supervisor \ Read Bio](/content/about-us/meet-the-team/jennifer-miller/index.html) [Dr. Ricardo Maggi \ Cofounder and vector-borne pathogens expert \ Read Bio](/content/about-us/meet-the-team/ricardo-maggi-phd/index.html) ## Galaxy offers cutting-edge pathogen testing for clinical trials, research, and diagnostic innovations. We provide pathogen testing and other diagnostic testing services for clinical trials, epidemiological studies, basic research initiatives, and new diagnostic test development, as requested by a variety of stakeholders including industry, civilian or military governmental agencies, academic and non-profit organizations. We offer both CLIA-validated molecular and serological assays testing for a growing range of zoonotic, vector-borne infectious agents, including _Bartonella spp_, _Borrelia spp_. ## Contract Research Services and Partnerships Galaxy Diagnostics offers pathogen testing services to research collaborators at universities and other biotech companies. Some of our recent research and testing partners include: Bayer Animal Health, Idexx Reference Labs, Focus on Lyme, Duke University, University of Minnesota, University of Washington’s Center for One Health Research, One Medicine Institute, a few drug development companies, and many others. If you or your organization is interested in collaborating on a project, please e-mail us at [contact@galaxydx.com](mailto:contact@galaxydx.com), for more information. ## Clinical Studies - See our Pathogen Testing in Action Galaxy Diagnostics partners with researchers across the country, offering advanced pathogen testing services to accelerate clinical trials, epidemiological studies, and innovative diagnostic developments. # _Borreliosis_ and doxycycline treatment disrupt gut microbiota and immune responses in nonhuman primates [View More ->](/content/borreliosis-and-doxycycline-treatment-disrupt-gut-microbiota-and-immune-responses-in-nonhuman-primates/index.html) # Human _Babesia_ odocoilei and _Bartonella_ spp. co‑infections in the Americas [View More ->](/content/human-babesia-odocoilei-and-bartonella-spp-co%e2%80%91infections-in-the-americas/index.html) # _Bartonella_ spp. Bacteremia and Rheumatic Symptoms in Patients from Lyme Disease–endemic Region [View More ->](/content/bartonella-spp-bacteremia-and-rheumatic-symptoms-in-patients-from-lyme-disease-endemic-region/index.html) # _Bartonella_ henselae and _Bartonella_ quintana antigens grown in liquid medium are inferior to cell culture-grown antigen for immunofluorescence IgG testing of patient sera [View More ->](/content/bartonella-henselae-and-bartonella-quintana-antigens-grown-in-liquid-medium-are-inferior-to-cell-culture-grown-antigen-for-immunofluorescence-igg-testing-of-patient-sera/index.html) # Using Digital PCR to Unravel the Occurrence of Piroplasmids, _Bartonella_ spp., and _Borrelia_ spp. in Wild Animals from Brazil [View More ->](/content/using-digital-pcr-to-unravel-the-occurrence-of-piroplasmids-bartonella-spp-and-borrelia-spp-in-wild-animals-from-brazil/index.html) # 60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025 [View More ->](/content/60-degrees-pharmaceuticals-to-submit-mums-minor-use-minor-species-designation-request-to-fda-for-tafenoquine-for-acute-canine-babesiosis-in-2025/index.html) # 60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion [View More ->](/content/60-degrees-pharmaceuticals-defines-potential-human-babesiosis-market-size-for-arakoda-tafenoquine-annual-max-tam-sales-of-245-million-cumulative-through-patent-expiration-1-1-billion/index.html) # 60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis [View More ->](/content/60-degrees-pharmaceuticals-selects-icahn-school-of-medicine-at-mount-sinai-as-central-clinical-trial-site-for-phase-ii-study-to-evaluate-tafenoquine-for-chronic-babesiosis/index.html) # Babesiosis Incidence in U.S. 6x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals [View More ->](/content/babesiosis-incidence-in-u-s-6x-higher-than-cdc-estimates-according-to-insurance-claims-study-commissioned-by-60-degrees-pharmaceuticals/index.html) ## Interested in collaboration, speaking opportunities, or research support? [contact@galaxydx.com](mailto:contact@galaxydx.com)